Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation
- 2 August 2004
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 34 (6) , 527-530
- https://doi.org/10.1038/sj.bmt.1704640
Abstract
The use of reduced intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT) can result in a significant decrease in early procedure-related toxicity in patients not eligible for standard myeloablative regimens. However, acute graft-versus-host disease (aGVHD) remains a matter of concern after RIC allo-SCT, and its incidence might be expected to be higher in elderly and high-risk patients. This report investigated mycophenolate mofetil (MMF) and cyclosporin A (CsA) combination (n=14) in comparison to CsA alone (n=20) for GVHD prophylaxis in cancer patients aged over 50 years (27 haematological malignancies and seven solid tumours) receiving an HLA-identical sibling antithymocyte-globulin (ATG)-based RIC allo-SCT. Baseline demographic characteristics and risk factors for aGVHD were comparable between both groups. Although MMF administration was not associated with any significant toxicity, the cumulative incidence of any form of GVHD was comparable between both groups (cumulative incidence of grade II–IV aGVHD, 50% (95% CI, 28–72%) for CsA alone, as compared to 64% (95% CI, 39–89%) to CsA and MMF, P=NS), suggesting that adjunction of MMF to CsA is feasible, but does not translate towards a significant reduction of aGVHD, at least in the context ATG-based RIC allo-SCT.Keywords
This publication has 26 references indexed in Scilit:
- Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumorsBlood, 2004
- Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimenLeukemia, 2003
- Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantationBlood, 2003
- Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin–based reduced-intensity preparative regimenBlood, 2003
- Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseasesBlood, 2003
- Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patientsBone Marrow Transplantation, 2002
- Allogeneic peripheral blood stem cell transplantation with reduced‐intensity conditioning: results of a prospective multicentre studyBritish Journal of Haematology, 2001
- Safety profile of mycophenolate mofetilBone Marrow Transplantation, 2000
- Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell TransplantationNew England Journal of Medicine, 2000
- Outcome After Allogeneic Bone Marrow Transplant for Leukemia in Older AdultsPublished by American Medical Association (AMA) ,1993